HBsAg Hijacks TBK1 to Suppress Interferon and Trigger Autophagy

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection afflicts approximately 350 million people worldwide, representing a major risk factor for liver cancer. Central to HBV’s persistence is its ability to evade the host’s innate immune response, especially the signaling pathways that culminate in type I interferon (IFN) production. Among the viral proteins, the hepatitis B surface antigen (HBsAg) is pivotal for viral entry, assembly, and immune modulation. Previous work suggested that HBV can manipulate innate immunity and autophagy, yet the precise molecular mechanisms underlying this crosstalk remained unresolved. The reference study (Luo et al., 2025) set out to determine how HBsAg regulates the antiviral response and autophagy machinery in hepatocytes, with a particular focus on TANK-binding kinase 1 (TBK1), a central node in both pathways.

Key Innovation from the Reference Study

The key innovation of this work is the identification of a direct mechanism by which HBsAg manipulates TBK1 to concurrently inhibit type I interferon production and induce early autophagy. Specifically, the study reveals that HBsAg interacts with the kinase domain of TBK1, promoting its dimerization and activating downstream autophagy signals, while simultaneously disrupting the TBK1–IRF3 complex required for IFN signaling. This dual modulation not only advances our understanding of HBV persistence but also highlights a novel viral strategy linking immune evasion with altered autophagic flux (Luo et al., 2025).

Methods and Experimental Design Insights

The investigators employed a multifaceted approach, combining in vivo and ex vivo systems. Key methodologies included:

• Generation of HBsAg transgenic mice and analysis of chronic HBV patient liver tissue to assess the clinical relevance of observed mechanisms.
• Primary hepatocyte culture and co-immunoprecipitation to map the interaction domains between HBsAg and TBK1.
• Use of the TBK1 inhibitor BX795 to dissect the contribution of TBK1 dimerization and kinase activity to autophagy induction and IFN suppression.
• Immunoblotting and immunofluorescence microscopy to quantify phosphorylation states of TBK1, IRF3, and the autophagy receptor p62.
• Reporter assays and chromatin immunoprecipitation to evaluate transcriptional regulation of SNAP29, a key mediator of autophagosome–lysosome fusion.

This robust design allowed the authors to confirm both the biochemical interactions and downstream functional consequences across multiple biological models.

Core Findings and Why They Matter

The study's principal discoveries can be summarized as follows:

• HBsAg promotes TBK1 dimerization, enhancing its autophagy-related kinase functions. This was evidenced by increased phosphorylation of sequestosome-1 (p62) and accumulation of autophagosomes in hepatocyte models.
• HBsAg disrupts TBK1–IRF3 complexes, resulting in impaired IRF3 phosphorylation and markedly reduced type I IFN production. This effect was observed both in vitro and in liver tissues from HBsAg transgenic mice and chronic HBV patients (reference).
• HBsAg impairs autophagosome–lysosome fusion via downregulation of the SNAP29 promoter, leading to incomplete autophagic flux. This prevents the degradation of autophagic cargo and may favor HBV replication.
• The use of TBK1 inhibitor BX795 demonstrated that the autophagy-inducing effects of HBsAg are TBK1-dependent, confirming causality.
• Clinical samples mirrored experimental results, with liver tissues from HBsAg-positive subjects displaying both suppressed IFNβ signaling and signatures of incomplete autophagy.

These findings clarify how HBV exploits host kinases to orchestrate immune evasion and persistence, providing a detailed mechanistic framework for future antiviral intervention strategies.

Comparison with Existing Internal Articles

Several internal resources contextualize and extend the findings of Luo et al. The article "HBsAg Hijacks TBK1 to Suppress Interferon and Trigger Autophagy" summarizes the main mechanistic insight—HBsAg’s direct manipulation of TBK1—as a foundation for exploring innovative antiviral targets. Meanwhile, "HBsAg Manipulates TBK1 to Suppress Interferon and Induce Autophagy" provides further commentary on the implications for immunometabolic and autophagy research, emphasizing how viral proteins co-opt core cellular processes. For researchers interested in the intersection of metabolism, cardiac stress, and autophagy, the article "Ranolazine: Anti-Ischemic Agent for Cardiac and Metabolic Research" discusses metabolic modulators such as Ranolazine in workflows that examine autophagic flux, though direct cross-talk with viral immunity is an emerging area.

Limitations and Transferability

Despite the comprehensive nature of the experimental design, several limitations must be considered:

• While in vivo and ex vivo models strengthen translational relevance, the majority of mechanistic dissection was performed in murine and primary hepatocyte systems, which may not fully recapitulate human hepatocyte responses in all contexts.
• The focus on HBsAg and TBK1 does not exclude additional HBV proteins or host factors from contributing to the observed phenomena.
• Clinical correlation is consistent but not causative; further studies in patient cohorts will be required to directly link these molecular events to HBV disease progression or therapeutic response.
• Given the complexity of autophagy and immune signaling, off-target effects of TBK1 inhibitors like BX795 should be considered in future translational research.

Nevertheless, the central conclusion—that HBV uses a single protein to coordinate immune suppression and altered autophagy—is strongly supported and highly relevant for designing antiviral strategies.

Protocol Parameters

• HBsAg overexpression: Use plasmid-based transfection in hepatocyte cultures or generate stably transgenic animal models for functional studies of innate immunity and autophagy.
• TBK1 inhibitor treatment: BX795 is typically used at 1–2 μM for 2–6 hours in primary hepatocytes or cell lines to selectively block TBK1 activity and probe dependence in HBsAg-driven phenotypes.
• Immunoblotting for phosphorylation: Analyze phosphorylation of TBK1 (Ser172), IRF3 (Ser396), and p62 (Ser403) to assess pathway activation or suppression.
• Autophagy flux assessment: Employ LC3-II turnover and p62 accumulation assays, with or without lysosomal inhibitors, to distinguish early autophagosome formation from complete autophagic degradation.
• Reporter assays: Luciferase-based promoter assays for IFNβ and SNAP29 can quantify transcriptional regulation in response to HBsAg expression or TBK1 modulation.

Why this cross-domain matters, maturity, and limitations

Although the reference study is centered on viral immunology and autophagy in hepatocytes, the intersection with metabolic modulation—such as shifts between fatty acid oxidation and glucose oxidation—has growing relevance. For instance, agents like Ranolazine, commonly used in cardiac ischemia research for their anti-ischemic and metabolic effects, are being explored for their impact on autophagic flux and cellular stress responses in non-cardiac tissues. However, direct evidence bridging Ranolazine’s metabolic modulation to HBV-induced autophagy or innate immune suppression is not yet established in the literature; thus, while metabolic context is intriguing, extrapolation should be made with caution.

Research Support Resources

For researchers seeking to model metabolic and autophagic processes in hepatic or cardiac systems, Ranolazine (SKU A8510) can be employed as an anti-ischemic agent with well-characterized effects on late sodium current inhibition and enhancement of glucose oxidation. Ranolazine’s validated solubility parameters (≥17.4 mg/mL in DMSO) and high purity make it suitable for in vitro and in vivo studies of metabolic stress and autophagy, as outlined in the internal workflow articles. When integrating Ranolazine into autophagy or cardiac ischemia research, it is recommended to prepare fresh solutions at the desired concentration (e.g., 10 mM in DMSO) and avoid long-term storage to preserve compound integrity. For precise product specifications and handling, consult the APExBIO product page.